Phase III Data In Suspected NASH Boost Madrigal’s Profile, But Bigger Data To Come

 
• By Joseph Haas
Madrigal office
Madrigal unveils additional data de-risking NASH candidate resmetirom • Source: Madrigal

More from Clinical Trials

More from R&D